Publications by authors named "Derek J Maetzold"
Background: A significant proportion of patients with American Joint Committee on Cancer (AJCC)-defined early-stage cutaneous melanoma have disease recurrence and die. A 31-gene expression profile (GEP) that accurately assesses metastatic risk associated with primary cutaneous melanomas has been described.
Objective: We sought to compare accuracy of the GEP in combination with risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.
A molecular test performed using fresh-frozen tissue was proposed for use in the prognosis of patients with pleural mesothelioma. The accuracy of the test and its properties was assessed under Clinical Laboratory Improvement Amendments-approved guidelines using FFPE tissue from an independent multicenter patient cohort. Concordance studies were performed using matched frozen and FFPE mesothelioma samples.
View Article and Find Full Text PDFArticle Synopsis
- The DecisionDx-Melanoma test analyzes 31 genes to determine the risk of metastasis in primary cutaneous melanoma patients, classifying them into low (Class 1) or high (Class 2) risk categories.
- A study reviewed the medical charts of 156 melanoma patients and found that 53% of them had management changes based on the test results, with Class 2 patients showing more significant adjustments than Class 1.
- The findings demonstrate that gene expression profiling affects clinical decision-making, as most management changes aligned with the patients' risk categories, although follow-up data to assess long-term impact was not available.
Background: A gene expression profile (GEP) test able to accurately identify risk of metastasis for patients with cutaneous melanoma has been clinically validated.
Objective: We aimed for assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients.
Methods: Reverse transcription polymerase chain reaction (RT-PCR) was performed to assess the expression of 31 genes from primary melanoma tumors, and SLNB outcome was determined from clinical data.